What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?

Core Insights - Summers Value Partners reported a net return of 20.4% for the Summers Value Fund LP in Q3 2025, outperforming the Russell 2000 Index ETF and the Russell 2000 Value Index ETF, which returned 12.4% and 12.5% respectively [1] - Year-to-date, the fund has increased by 4.9%, while the Russell 2000 Index ETF and the Russell 2000 Value Index ETF have returned 10.3% and 8.9% respectively [1] Company Highlights: Ligand Pharmaceuticals Incorporated - Ligand Pharmaceuticals (NASDAQ:LGND) achieved a one-month return of 11.58% and an impressive 85.60% increase in share value over the past 52 weeks, closing at $207.05 per share with a market capitalization of $4.075 billion on November 18, 2025 [2] - Ligand operates as a royalty aggregator in the pharmaceutical industry, requiring minimal capital for growth as its partners cover product development and commercialization costs [3] - In Q3 2025, Ligand reported total revenue and other income of $115.5 million, a significant increase from $51.8 million in Q3 2024 [4]